Strong hint towards Amgen licensing a bisantrene+carfilzomib coformulation (that we hold the patent for) here. I love it.
More and more I see the pieces coming together for a series of license-based transactions and partnerships by cancer indication. Cash, royalties, biobux, then a major transaction down the line.
Strong hint towards Amgen licensing a bisantrene+carfilzomib...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.090(5.06%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.63 | $449.0K | 263.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2300 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 8176 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |